BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31423157)

  • 1. ST6GAL1: A key player in cancer.
    Garnham R; Scott E; Livermore KE; Munkley J
    Oncol Lett; 2019 Aug; 18(2):983-989. PubMed ID: 31423157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
    Scott E; Archer Goode E; Garnham R; Hodgson K; Orozco-Moreno M; Turner H; Livermore K; Putri Nangkana K; Frame FM; Bermudez A; Jose Garcia Marques F; McClurg UL; Wilson L; Thomas H; Buskin A; Hepburn A; Duxfield A; Bastian K; Pye H; Arredondo HM; Hysenaj G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Singh S; Johnston EW; Punwani S; Knight B; McCullagh P; McGrath J; Crundwell M; Harries L; Heer R; Maitland NJ; Whitaker H; Pitteri S; Troyer DA; Wang N; Elliott DJ; Drake RR; Munkley J
    J Pathol; 2023 Sep; 261(1):71-84. PubMed ID: 37550801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ST6GAL1 sialyltransferase promotes acinar to ductal metaplasia and pancreatic cancer progression.
    Bhalerao N; Chakraborty A; Marciel MP; Hwang J; Britain CM; Silva AD; Eltoum IE; Jones RB; Alexander KL; Smythies LE; Smith PD; Crossman DK; Crowley MR; Shin B; Harrington LE; Yan Z; Bethea MM; Hunter CS; Klug CA; Buchsbaum DJ; Bellis SL
    JCI Insight; 2023 Oct; 8(19):. PubMed ID: 37643018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1.
    Kurz E; Chen S; Vucic E; Baptiste G; Loomis C; Agrawal P; Hajdu C; Bar-Sagi D; Mahal LK
    Mol Cell Proteomics; 2021; 20():100160. PubMed ID: 34634466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
    Hodgson K; Orozco-Moreno M; Goode EA; Fisher M; Garnham R; Beatson R; Turner H; Livermore K; Zhou Y; Wilson L; Visser EA; Pijnenborg JF; Eerden N; Moons SJ; Rossing E; Hysenaj G; Krishna R; Peng Z; Nangkana KP; Schmidt EN; Duxfield A; Dennis EP; Heer R; Lawson MA; Macauley M; Elliott DJ; Büll C; Scott E; Boltje TJ; Drake RR; Wang N; Munkley J
    EBioMedicine; 2024 May; 104():105163. PubMed ID: 38772281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ST6GAL1 inhibits metastasis of hepatocellular carcinoma via modulating sialylation of MCAM on cell surface.
    Zou X; Lu J; Deng Y; Liu Q; Yan X; Cui Y; Xiao X; Fang M; Yang F; Sawaki H; Sato T; Tan B; Lu X; Feng B; Kuno A; Narimatsu H; Gao C; Zhang Y
    Oncogene; 2023 Feb; 42(7):516-529. PubMed ID: 36528750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of core fucosylation in both ST6GAL1 and its substrate enhances glycoprotein sialylation in mice.
    Huang G; Li Z; Li Y; Liu G; Sun S; Gu J; Kameyama A; Li W; Dong W
    Biochem J; 2020 Mar; 477(6):1179-1201. PubMed ID: 32141499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics.
    Ankenbauer KE; Rao TC; Mattheyses AL; Bellis SL
    J Biol Chem; 2023 Oct; 299(10):105217. PubMed ID: 37660914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of α2,6-sialyltransferases for sialylation of therapeutic proteins.
    Janesch B; Saxena H; Sim L; Wakarchuk WW
    Glycobiology; 2019 Sep; 29(10):735-747. PubMed ID: 31281932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood-Borne ST6GAL1 Regulates Immunoglobulin Production in B Cells.
    Irons EE; Punch PR; Lau JTY
    Front Immunol; 2020; 11():617. PubMed ID: 32391003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.
    Dorsett KA; Jones RB; Ankenbauer KE; Hjelmeland AB; Bellis SL
    J Ovarian Res; 2019 Oct; 12(1):93. PubMed ID: 31610800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese hamster ovary (CHO) host cell engineering to increase sialylation of recombinant therapeutic proteins by modulating sialyltransferase expression.
    Lin N; Mascarenhas J; Sealover NR; George HJ; Brooks J; Kayser KJ; Gau B; Yasa I; Azadi P; Archer-Hartmann S
    Biotechnol Prog; 2015; 31(2):334-46. PubMed ID: 25641927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth.
    Gc S; Tuy K; Rickenbacker L; Jones R; Chakraborty A; Miller CR; Beierle EA; Hanumanthu VS; Tran AN; Mobley JA; Bellis SL; Hjelmeland AB
    JCI Insight; 2022 Nov; 7(21):. PubMed ID: 36345944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficiency in ST6GAL1, one of the two α2,6-sialyltransferases, has only a minor effect on the pathogenesis of prion disease.
    Makarava N; Katorcha E; Chang JC; Lau JTY; Baskakov IV
    Front Mol Biosci; 2022; 9():1058602. PubMed ID: 36452458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway.
    Yuan Q; Chen X; Han Y; Lei T; Wu Q; Yu X; Wang L; Fan Z; Wang S
    Int J Cancer; 2018 Nov; 143(9):2319-2330. PubMed ID: 29981167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma.
    Pousset D; Piller V; Bureaud N; Monsigny M; Piller F
    Cancer Res; 1997 Oct; 57(19):4249-56. PubMed ID: 9331085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the ST6GAL1 sialyltransferase in regulating ovarian cancer cell metabolism.
    Jones RB; Silva AD; Ankenbauer KE; Britain CM; Chakraborty A; Brown JA; Ballinger SW; Bellis SL
    Glycobiology; 2023 Oct; 33(8):626-636. PubMed ID: 37364046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness.
    Hait NC; Maiti A; Wu R; Andersen VL; Hsu CC; Wu Y; Chapla DG; Takabe K; Rusiniak ME; Bshara W; Zhang J; Moremen KW; Lau JTY
    Cancer Gene Ther; 2022 Nov; 29(11):1662-1675. PubMed ID: 35676533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG and leukocytes: Targets of immunomodulatory α2,6 sialic acids.
    Jones MB
    Cell Immunol; 2018 Nov; 333():58-64. PubMed ID: 29685495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent Golgi trafficking limits B cell-mediated IgG sialylation.
    Glendenning LM; Zhou JY; Reynero KM; Cobb BA
    J Leukoc Biol; 2022 Dec; 112(6):1555-1566. PubMed ID: 35726710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.